Gemcitabine
- PDF / 169,636 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 166 Views
1 S
Cholangitis, sepsis and upper gastrointestinal bleeding: 2 case reports In a retrospective study involving 149 patients (treated with multi-fraction stereotactic ablative radiotherapy between February 2007 and August 2018), two patients [ages and sexes not stated] were described, who developed cholangitis, sepsis or upper gastrointestinal bleeding while receiving gemcitabine for pancreatic adenocarcinoma [routes and dosages not stated; not all times to reactions onsets and outcomes stated]. The patients, who had pancreatic adenocarcinoma, started receiving cyclical treatment with gemcitabine, along with concomitant stereotactic ablative radiotherapy (SABR) at 30Gy in five fractions. One of the two patients had undergone biliary stent placement prior to SABR, and two months later, the patient developed grade 4 cholangitis, which evolved into a sepsis eventually, requiring ICU admission. The remaining one patient developed grade 5 toxicity in the form of upper gastrointestinal bleeding 5 months following SABR completion. The patient with upper gastrointestinal bleeding underwent angiography, which demonstrated that bleeding was caused by fistulised pseudoaneurysm of the superior mesenteric artery; bleeding could not be controlled despite arterial embolisation, and the patient died of the upper gastrointestinal bleeding. Toesca DAS, et al. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiotherapy and 803506781 Oncology 152: 63-69, Nov 2020. Available from: URL: http://doi.org/10.1016/j.radonc.2020.07.053
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
